Apellis Pharmaceuticals (APLS) Peer Comparison
$41.03
$0.00 (0.00%)As on 15-May-2026 16:00EDT
Market cap
$5,253 Mln
Revenue (TTM)
$1,105 Mln
P/E Ratio
38.3
P/B Ratio
12.7
Div. Yield
0 %
Edit
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
5,253 | 12,818 | 12,550 | 11,361 | 12,122 |
Revenue ($ Mln) |
1,105 | 692 | 831 | 5,020 | 432 |
Net Profit ($ Mln) |
133.27 | -696.24 | 54.90 | -199.00 | -136.72 |
Net Margin (%) |
12.06 | -100.64 | 6.61 | -3.96 | -31.66 |
RoE (%) |
32.66 | -- | 8.11 | -3.03 | -30.32 |
Price to Earnings |
38.35 | -- | 258.00 | -- | -- |
Price-To-Book |
12.66 | 123.68 | 18.00 | 1.73 | 23.58 |
Income Statement ($ Mln)
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,105.28 | 691.84 | 830.81 | 5,020.00 | 431.80 |
|
Cost of Revenue
|
109.16 | 47.45 | 14.09 | 2,380.00 | 207.41 |
|
Gross Profit
|
901.55 | 473.81 | 748.43 | 2,050.00 | 191.00 |
|
Operating Expenses
|
831.19 | 1,187.86 | 810.32 | 2,178.00 | 362.16 |
|
Operating Profit (EBIT)
|
165.22 | -543.47 | 6.41 | 462.00 | -137.77 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
135.15 | -706.17 | 26.37 | -166.00 | -135.85 |
|
Provision for Tax
|
1.88 | -7.73 | -35.26 | 33.00 | 0.24 |
|
Profit after Tax (Net Income)
|
133.27 | -696.24 | 54.90 | -199.00 | -136.72 |
|
Minority Interest
|
0.00 | 10.15 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities ($ Mln)
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
414.92 | -2,515.22 | 705.78 | 6,588.00 | 445.74 |
|
Minority Interest
|
0.00 | 10.15 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
384.16 | 2,832.54 | 29.12 | 5,121.00 | 106.44 |
|
Current Liabilities
|
283.45 | 890.65 | 153.80 | 1,852.00 | 120.26 |
|
Total Liabilities
|
1,075.26 | 936.03 | 836.65 | 13,358.00 | 641.86 |
Assets ($ Mln)
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
54.51 | 124.16 | 449.03 | 9,764.00 | 351.14 |
|
Current Assets
|
1,028.02 | 1,093.14 | 439.68 | 3,797.00 | 321.30 |
|
Total Assets
|
1,075.26 | 936.03 | 836.65 | 13,358.00 | 641.86 |
|
Total Debt*
|
475.76 | 2,493.78 | 9.42 | 3,918.00 | 93.59 |
|
Net Current Assets
|
744.57 | 202.49 | 285.87 | 1,945.00 | 201.04 |
Cashflow ($ Mln)
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
45.33 | -445.91 | 142.00 | 560.00 | -47.63 |
|
Cash Flow from Investing Activities
|
-0.31 | -24.49 | 69.76 | -279.00 | -24.76 |
|
Cash from Financing Activities
|
8.88 | 359.29 | -220.37 | -275.00 | 28.54 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
2.88 | -159.44 | 14.87 | -2.21 | -13.30 |
|
ROE (%)
|
32.66 | 41.15 | 8.11 | -3.03 | -30.32 |
|
ROA (%)
|
11.33 | -41.39 | 5.52 | -1.30 | -17.95 |
|
EBIT Margin (%)
|
16.17 | -89.09 | 3.17 | 1.61 | -30.84 |
|
Net Margin (%)
|
12.06 | -100.64 | 6.61 | -3.96 | -31.66 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
42.46 | 193.38 | 16.02 | 11.95 | 19.19 |
|
EBIT Growth (%)
|
200.49 | 5.05 | -79.11 | -90.61 | -57.38 |
|
Net Profit Growth (%)
|
159.58 | 10.33 | -58.66 | -145.85 | -60.49 |
|
EPS Growth (%)
|
158.88 | 12.58 | -62.44 | -146.42 | -52.59 |
|
Book Value Growth (%)
|
151.52 | -36.90 | 12.98 | -3.87 | -8.64 |
Valuation Ratios
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
141.40 | -20.69 | 41.86 | -48.47 | -21.89 |
|
Price / Book Value
|
8.55 | -7.27 | 6.44 | 1.72 | 3.60 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
45.49 | -25.60 | 55.67 | 21.77 | -30.81 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.87 | -0.77 | 0.00 | 0.58 | 0.00 |
|
Short term debt to equity ratio
|
0.24 | -0.22 | 0.00 | 0.01 | 0.02 |
|
Current Ratio
|
3.63 | 1.23 | 2.86 | 2.05 | 2.67 |
|
Quick Ratio
|
3.16 | 1.17 | 2.77 | 1.10 | 2.38 |
|
Interest Coverage
|
4.10 | -6.86 | -- | 0.36 | -- |
Operating Efficiency Ratios
| Apellis Pharmaceuticals (APLS) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Twist Bioscience Corp (TWST) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
40.27 | 36.78 | 9.26 | 22.95 | 15.23 |
|
Asset Turnover
|
0.94 | 0.41 | 0.84 | 0.33 | 0.57 |
|
Receivable days
|
116.07 | 52.44 | 28.27 | 70.73 | 44.72 |
|
Inventory Days
|
401.99 | 172.81 | 355.76 | 226.89 | 51.56 |
|
Payable days
|
170.36 | 296.14 | 785.55 | 45.50 | 12.52 |
|
Cash Conversion Cycle
|
347.70 | -70.89 | -401.52 | 252.12 | 83.76 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
